Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964619 | 0.88 | TP53 (0.52) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL1062956 | 0.85 | TP53 (0.49) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL1062664 | 0.84 | TP53 (0.48) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL1065628 | 0.80 | HTR6 (0.64) | THRBKMT2AALDH1A1MEN1MAPK1 | |
| SCHEMBL5814581 | 0.80 | HTR6 (0.40) | KMT2AALDH1A1MEN1MAPK1SMN1; SMN2 | |
| SCHEMBL12847947 | 0.78 | HTR6 (0.57) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL2966777 | 0.78 | HTR6 (0.72) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL29405276 | 0.78 | HTR6 (0.72) | TP53THRBKMT2AALDH1A1MEN1 | |
| SCHEMBL1063102 | 0.78 | PKM (0.49) | KMT2AALDH1A1MEN1MAPK1SMN1; SMN2 | |
| SCHEMBL1062492 | 0.77 | HTR6 (0.47) | TP53THRBKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-7582767-B2 | Substituted sulphonamide compound and uses thereof | BIOVITRUM AB (PUBL.) (SE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896460-B1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | BIOVITRUM AB PUBL (SE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1896460-A1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293361-A1 | N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006134150-A1 | BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287291-A1 | Compounds | HTR6, HTR1B, HTR1A | TP53 4487/4885THRB 1033/4885KMT2A 3728/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | TP53 4239/4885THRB 1924/4885KMT2A 3354/4885 |
| US-20060293361-A1 | N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain | GPR119, CNR2, SULT1E1 | TP53 4884/4885THRB 899/4885KMT2A 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.